142 related articles for article (PubMed ID: 18771638)
1. New therapeutic agents in the management of HIV: an overview of darunavir for clinicians.
Rotty J; Hoy J
Sex Health; 2008 Sep; 5(3):235-41. PubMed ID: 18771638
[TBL] [Abstract][Full Text] [Related]
2. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
3. Darunavir.
El-Atrouni WI; Temesgen Z
Drugs Today (Barc); 2007 Oct; 43(10):671-9. PubMed ID: 17987220
[TBL] [Abstract][Full Text] [Related]
4. [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Arazo Garcés P; Omiste Sanvicente T
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():23-31. PubMed ID: 19195456
[TBL] [Abstract][Full Text] [Related]
5. Darunavir in the treatment of HIV-1 infection: a viewpoint by Mark Holodniy.
Holodniy M
Drugs; 2007; 67(18):2803. PubMed ID: 18062725
[No Abstract] [Full Text] [Related]
6. [Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():24-5. PubMed ID: 19024912
[No Abstract] [Full Text] [Related]
7. [Position of darunavir in antiretroviral therapy].
Clotet B
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():61-2. PubMed ID: 19195461
[No Abstract] [Full Text] [Related]
8. Darunavir: a nonpeptidic antiretroviral protease inhibitor.
McCoy C
Clin Ther; 2007 Aug; 29(8):1559-76. PubMed ID: 17919539
[TBL] [Abstract][Full Text] [Related]
9. Anti-HIV agents. Darunavir shows its strength.
TreatmentUpdate; 2007; 19(5):2-4. PubMed ID: 17955613
[No Abstract] [Full Text] [Related]
10. Darunavir (TMC114): a new HIV-1 protease inhibitor.
Molina JM; Hill A
Expert Opin Pharmacother; 2007 Aug; 8(12):1951-64. PubMed ID: 17696796
[TBL] [Abstract][Full Text] [Related]
11. Darunavir in the treatment of HIV-1 infection: a viewpoint by Renslow Sherer.
Sherer R
Drugs; 2007; 67(18):2802-3. PubMed ID: 18062726
[No Abstract] [Full Text] [Related]
12. [Chemical characteristics, mechanism of action and antiviral activity of darunavir].
Pasquau Liaño J; Hidalgo Tenorio C
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():3-9. PubMed ID: 19195453
[TBL] [Abstract][Full Text] [Related]
13. Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance.
Taiwo BO; Hicks CB
AIDS Read; 2007 Mar; 17(3):151-6, 159-61. PubMed ID: 17396332
[TBL] [Abstract][Full Text] [Related]
14. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
[No Abstract] [Full Text] [Related]
15. Darunavir: a critical review of its properties, use and drug interactions.
Ruela Corrêa JC; D'Arcy DM; dos Reis Serra CH; Nunes Salgado HR
Pharmacology; 2012; 90(1-2):102-9. PubMed ID: 22797653
[TBL] [Abstract][Full Text] [Related]
16. Darunavir: a second-generation protease inhibitor.
Busse KH; Penzak SR
Am J Health Syst Pharm; 2007 Aug; 64(15):1593-602. PubMed ID: 17646561
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV agents. TMC114--an overview.
TreatmentUpdate; 2005; 17(5):2-3. PubMed ID: 17219654
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Clotet B; Bellos N; Molina JM; Cooper D; Goffard JC; Lazzarin A; Wöhrmann A; Katlama C; Wilkin T; Haubrich R; Cohen C; Farthing C; Jayaweera D; Markowitz M; Ruane P; Spinosa-Guzman S; Lefebvre E;
Lancet; 2007 Apr; 369(9568):1169-78. PubMed ID: 17416261
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a reduced dose of darunavir/ritonavir in a small cohort of antiretroviral-naïve HIV-infected patients.
Lanzafame M; Lattuada E; Rigo F; Vento S
AIDS Patient Care STDS; 2013 Jun; 27(6):315-6. PubMed ID: 23701201
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
Boffito M; Miralles D; Hill A
HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
